nyuuzyou/wikis huggingface dataset:
Rociletinib (CO-1686)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Non-small cell lung cancer===
# Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. link to original article EuroPMC NCT01526928
==Also known as==
*Code name: CO-1686
Category:Drugs
Category:Oral medications
Category:EGFR inhibitors
Category:Halted drugs
Rolapitant (Varubi)

==General information==
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist.
Route: PO, IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
==History of changes in FDA indication==
*2015-09-01: Initial FDA approval "in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy."
*2017-10-25: IV formulation FDA approved
==History of changes in EMA indication==
*2017-04-20: Initial authorization as Varuby
*2020-01-23: Withdrawn at the manufacturer's request, for commercial reasons
==Pivotal studies==
# Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep;16(9):1079-89. Epub 2015 Aug 10. EuroPMC
# Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015 Sep;16(9):1071-8. Epub 2015 Aug 10. EuroPMC
==Also known as==
*Code names: SCH-619734
*Brand names: Varubi, Varubi IV, Varuby
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Neurokinin 1 (NK1) antagonists
Category:FDA approved in 2015
Category:EMA approved in 2017
Category:EMA withdrawn in 2020
Romidepsin (Istodax)

==General information==
Class/mechanism: Histone deacetylase (HDAC) inhibitor. HDACs normally catalyze removal of acetyl groups from acetylated lysine residues in histones and non-histone proteins, which helps to regulate gene expression. Inhibition of histone deacetylases results in hyperacetylation of histones and modulates gene expression by creating an open chromatin state that leads to expression of previously silenced genes. Although the mechanism of action is not fully understood, inhibiting HDACs has been observed to result in cell cycle arrest and apoptosis of cancer cells.Romidepsin (Istodax) package insertRomidepsin (Istodax) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Cutaneous T-cell lymphoma
*Peripheral T-cell lymphoma Note: this indication remains in Japan but was withdrawn from the USA.
==Patient drug information==
*Romidepsin (Istodax) package insert PDF pages 8-9
*Romidepsin (Istodax) patient drug information (UpToDate)Romidepsin (Istodax) patient drug information (UpToDate)
==History of changes in FDA indication==
===Cutaneous T-cell lymphoma===
* 2009-11-05: Initial FDA approval for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. (Based on NIH 01-C-0049CTCL and GPI-04-0001)
===Peripheral T-cell lymphoma - WITHDRAWN===
* 2011-06-16: Additional indication for treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. (Based on GPI-06-0002)
**2021-07-30: Approval for treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy withdrawn. (Based on LYSA Ro-CHOP)
==History of changes in Health Canada indication==
*2013-10-16: Initial notice of compliance with conditions for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one prior systemic therapy.
==History of changes in PMDA indication==
*2017-07-03: New approval for the treatment of relapsed or refractory peripheral T-cell lymphoma.
==Also known as==
*Code names: FK-228, FR-901228, NSC-630176
*Generic name: depsipeptide
*Brand name: Istodax
==References==
Category:Drugs
Category:Intravenous medications
Category:HDAC inhibitors
Category:Cutaneous T-cell lymphoma medications
Category:Peripheral T-cell lymphoma medications
Category:FDA approved in 2009
Category:Health Canada approved in 2013
Category:PMDA approved in 2017
Romiplostim (Nplate)

==General information==
Class/mechanism: Thrombopoietin (TPO/cMpl) receptor agonist. Romiplostim is an Fc-peptide fusion protein (peptibody) that interacts with the TPO receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.Romiplostim (Nplate) package insertRomiplostim (Nplate) package insert (locally hosted backup)Nplate manufacturer's website
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Aplastic anemia
*Immune thrombocytopenia
==Patient drug information==
*Romiplostim (Nplate) package insert
*Romiplostim (Nplate) patient drug information (Chemocare)Romiplostim (Nplate) patient drug information (Chemocare)
*Romiplostim (Nplate) patient drug information (UpToDate)Romiplostim (Nplate) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2008-08-22: Initial approval
* 2018-12-14: Approved for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
==History of changes in EMA indication==
*2009-02-04: Initial authorization
==History of changes in PMDA indication==
*2019-06-18: New indication and a new dosage for the treatment of aplastic anemia in patients who have not responded sufficiently to conventional treatments.
==Also known as==
*Brand name: Nplate
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Hematopoietic growth factors
Category:Megakaryocyte growth factors
Category:Hematology medications
Category:Aplastic anemia medications
Category:Immune thrombocytopenia medications
Category:FDA approved in 2008
Category:EMA approved in 2009
Ropeginterferon alfa-2b (Besremi)

==General information==
Class/mechanism per NCI Drug Dictionary: A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates.
Route: SC
Extravasation: n/a
==Diseases for which it is used==
*Polycythemia vera
==History of changes in FDA indication==
*2021-11-12: Initial approval for adults with polycythemia vera. (Based on PEGINVERA)
==History of changes in EMA indication==
*2019-02-15: Initial authorization
==History of changes in PMDA indication==
*2023-03-27: Initial approval
==Also known as==
*Code name: AOP-2014
*Generic name: ropeginterferon alfa-2b-njft
*Brand name: Besremi
Category:Drugs
Category:Subcutaneous medications
Category:Pegylated medications
Category:Interferon alfas
Category:Polycythemia vera medications
Category:EMA approved in 2019
Category:FDA approved in 2021
Category:PMDA approved in 2023
Rosai-Dorfman-Destombes disease

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==Consensus guidelines==
*2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease link to PMC article EuroPMC
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Histiocytic Neoplasms.
=All lines of therapy=
==Cobimetinib monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence
Diamond et al. 2019 (MSK 15-216)	2016 to not reported	Phase 2, fewer than 20 pts in this arm (RT)
Note: there were N=2 patients with this type of histiocytosis.
====Targeted therapy====
*Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
28-day cycles
===References===
# MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02649972
Category:Rosai-Dorfman-Destombes disease regimens
Category:Disease-specific pages
Category:Histiocytoses
Rusfertide (PTG-300)

==Mechanism of action==
Hepcidin mimetic
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Polycythemia vera===
#REVIVE: Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R; REVIVE Trial Investigators. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22;390(8):723-735. link to original article EuroPMC NCT04057040
Category:Drugs
Category:Subcutaneous medications
Category:Polycythemia vera medications (investigational)
Category:Stub
SUNY Health Science Center at Brooklyn Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Division of Hematology/Oncology in the Department of Medicine at Columbia prepares its fellows to be creative and productive contributors as researchers and clinicians. Our program provides a broad-based clinical training and rigorous development of a research project with opportunities to work with world-class investigators in an outstanding Ivy League University."
==Basic information==
Name: SUNY Health Science Center at Brooklyn Program (SUNY Downstate) Hematology Oncology Fellowship
Fellowship program website: https://www.downstate.edu/medicine/education/fellowships/hematology.html
ACGME ID: 1553511043
===Leadership===
*Program Director: Carol Luhrs, MD
===Fellowship Coordinator===
Lois Cooper
SUNY Downstate Medical Center
MSC 20
Room B5-495
450 Clarkson Avenue
Brooklyn N.Y. 11203
Phone: (718) 613-8678
Fax: (718) 270-1578
Email: lois.cooper@downstate.edu
==Application process and requirements==
https://www.downstate.edu/medicine/education/fellowships/hematology.html
===Process===
*Applications accepted starting in: July
*Application deadline:
*Applications submitted through ERAS
===Requirements===
*Accepts J1 Visa
==Statistics==
*Number of fellowship positions available per year: 4-5 per year
*Board certification eligibility upon fellowship completion: (depending on what fellow chooses) Hematology and Oncology, Hematology, or Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
5 months each of Clinical Hematology and Clinical Medical Oncology; Continuity clinic
===Year 2===
5 months each of Clinical Hematology and Oncology, One month of Research elective and 2 week rotation in multiple myeloma at MSKCC; Continuity clinic
===Year 3===
One month Stem Cell Transplant at MSKCC; One month each of Clinical Hematology and Clinical Medical Oncology; 8 months of Research in Clinical or Basic Science; Continuity clinic
==Affiliated medical facilities==
Kings County Hospital Center
University Hospital Brooklyn
Brooklyn campus of VA-New York Harbor Healthcare System
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Samarium-153 (Quadramet)

==General information==
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.Samarium-153 (Quadramet) package insertSamarium-153 (Quadramet) package insert (locally hosted backup)Samarium-153 (Quadramet) alternative package insertSamarium-153 (Quadramet) alternative package insert (locally hosted backup)Quadramet manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Osteosarcoma
*Prostate cancer
==Patient drug information==
*Samarium-153 (Quadramet) patient drug information (UpToDate)Samarium-153 (Quadramet) patient drug information (UpToDate)
==History of changes in FDA indication==
*1997-03-28: Initial approval for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
==History of changes in EMA indication==
*1998-02-04: Initial authorization
==Also known as==
*Generic names: 153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), lexidronam pentasodium, samarium [153 SM], samarium Sm 153 lexidronam injection
*Brand name: Quadramet
==References==
Category:Drugs
Category:Intravenous medications
Category:Radiotherapy medications
Category:Osteosarcoma medications 
Category:Prostate cancer medications
Category:FDA approved in 1997
Category:EMA approved in 1998
Sapacitabine (CS-682)

==Mechanism of action==
Pyrimidine analog
==Preliminary results==
===Acute myeloid leukemia===
# CYC682-06: Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov;13(11):1096-104. Epub 2012 Oct 15. link to original article link to PMC article EuroPMC NCT00590187
==Also known as==
*Code name: CS-682
Category:Drugs
Category:Oral medications
Category:Pyrimidine analogs
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs
Sarcomatoid renal cell carcinoma

Back to Top
Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
=Metastatic disease, first-line=
==Doxorubicin & Gemcitabine==
===Regimen===
Study 	Dates of enrollment	Evidence
Haas et al. 2012 (ECOG 8802)	2004-2007 	Phase 2
====Chemotherapy====
*Doxorubicin (Adriamycin) 50 mg/m2 IV push once on day 1
*Gemcitabine (Gemzar) 1500 mg/m2 IV over 30 minutes once on day 1
====Supportive therapy====
*One of the following:
**Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10
**Pegfilgrastim (Neulasta) 6 mg SC once on day 2
14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)
===References===
# ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00068393
==Gemcitabine & Sunitinib==
===Regimen===
Study 	Dates of enrollment	Evidence
Michaelson et al. 2015 (MGH 07-212)	2007-2013 	Phase 2
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
====Targeted therapy====
*Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 14
21-day cycles
===References===
# MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article EuroPMC NCT00556049
Category:Sarcomatoid renal cell carcinoma regimens
Category:Histology-specific pages
Category:Renal cell carcinomas
Sargramostim (Leukine)

==General information==
Class/mechanism: Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF), hematopoietic growth factor. Sargramostim binds to cell surface receptors and stimulates survival, proliferation, and differentiation of hematopoietic progenitor cells. In addition to triggering the proliferation of neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells, GM-CSF has also been observed to activate mature granulocytes and macrophages.Sargramostim (Leukine/GM-CSF) package insertSargramostim (Leukine/GM-CSF) package insert (locally hosted backup)Leukine manufacturer's website
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
Note: sargramostim does not have a known direct antineoplastic effect. However, it has been used as an adjunct for immunotherapy trials.
*Melanoma
*Neuroblastoma
==Patient drug information==
*Sargramostim (Leukine/GM-CSF) package insert
*Sargramostim (Leukine/GM-CSF) patient drug information (Chemocare)Sargramostim (Leukine/GM-CSF) patient drug information (Chemocare)
*Sargramostim (Leukine/GM-CSF) patient drug information (UpToDate)Sargramostim (Leukine/GM-CSF) patient drug information (UpToDate)
==Also known as==
*Generic names: GMCSF, GM-CSF, granulocyte macrophage colony stimulating factor
*Brand name: Leukine
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Intravenous medications
Category:Granulocyte macrophage colony-stimulating factors
Category:Melanoma medications
Category:Neuroblastoma medications
Category:FDA approved in 1991
Scopolamine (Scopoderm)

=Mechanism of action=
Scopolamine is a tropane alkaloid drug with muscarinic antagonist effects, including emesis prevention. Popular due to the fact that it is a patch so does not have to be given by the oral route, but can have many intolerable side effects. No known antineoplastic properties.
=Also known as=
*Brand names: Scopoderm, Transderm Scop
Category:Drugs
Category:Topical medications
Category:Emesis prevention
Category:Muscarinic receptor antagonist
Category:FDA approved in 1979